KRAS mutation predict response and outcome in advanced non-small cell lung carcinoma without driver alterations receiving PD-1 blockade immunotherapy combined with platinum-based chemotherapy: a retrospective cohort study from China

BACKGROUND: The selection of patients for immunotherapy remains challenging given the lack of highly specific and highly sensitive biomarkers. Kirsten rat sarcoma (KRAS) mutation is the most frequent molecular alteration found in advanced non-small cell lung carcinoma (NSCLC). We explored whether KR...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Qianni, Zhou, Qi, Zhao, Shicai, Wu, Peng, Shi, Ping, Zeng, Jia, Xiong, Xiaomin, Chen, Haiwen, Kittaneh, Muaiad, Bravaccini, Sara, Zanoni, Michele, Zhou, Chengzhi, Zhang, Jiexia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9641043/
https://www.ncbi.nlm.nih.gov/pubmed/36386464
http://dx.doi.org/10.21037/tlcr-22-655

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9641043/
https://www.ncbi.nlm.nih.gov/pubmed/36386464
http://dx.doi.org/10.21037/tlcr-22-655

Ejemplares similares